Alberto Terron
Cadiz, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial.
Journal: PloS one
Published: November 11, 2024
Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
Journal: International journal of antimicrobial agents
Published: January 22, 2024
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Journal: Viruses
Published: January 20, 2022
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.
Journal: The Journal of antimicrobial chemotherapy
Published: March 06, 2018
Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice.
Journal: AIDS research and human retroviruses
Published: June 03, 2016
Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.
Journal: HIV medicine
Published: March 30, 2016
Monotherapy with darunavir/ritonavir is effective and safe in clinical practice.
Journal: Journal of the International AIDS Society
Published: November 15, 2014
CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study.
Journal: Journal of the International AIDS Society
Published: November 14, 2014
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Journal: The Journal of infectious diseases
Published: July 19, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026